Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

70.92
-0.3800-0.53%
Post-market: 70.50-0.4200-0.59%17:04 EDT
Volume:3.24M
Turnover:229.27M
Market Cap:3.98B
PE:6.39
High:71.04
Open:70.96
Low:69.71
Close:71.30
52wk High:74.59
52wk Low:59.47
Shares:56.10M
Float Shares:56.10M
Volume Ratio:6.19
T/O Rate:5.78%
Dividend:0.80
Dividend Rate:1.13%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.42
PE(LYR):23.18

Loading ...

Merck & Company (MRK) Receives a Buy from BMO Capital

TIPRANKS
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (VSTM), Ultragenyx Pharmaceutical (RARE) and UnitedHealth (UNH)

TIPRANKS
·
Yesterday

Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ) and NeoGenomics (NEO)

TIPRANKS
·
Yesterday

Dow Falls Over 300 Points As Treasury Yields Surge: Investor Sentiment Weakens, Fear & Greed Index Remains In ‘Neutral’ Zone

Benzinga Earnings
·
Yesterday

Medicare Open Enrollment Starts Next Week. Why It's Really Important to Shop This Year.

Dow Jones
·
Yesterday

Health Care up on Defensive Bias

Dow Jones
·
Yesterday

3 ‘Strong Buy’ Dividend Aristocrat Stocks on Analysts’ Watch List

TIPRANKS
·
Yesterday

Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Yesterday

Eli Lilly & Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Sector Update: Healthcare

MT Newswires Live
·
Yesterday

Exchange-Traded Funds Lower as US Equities Decline After Midday

MT Newswires Live
·
Yesterday

Moderna, Merck Climb on Collaboration with Tempus

Reuters
·
Yesterday

Merck's Keytruda is Dealt a Legal Setback. It's Good News for This Biotech Stock.

Dow Jones
·
Yesterday

Eli Lilly and Co Stock (LLY) Moved Up by 3.94% on Oct 7: Facts Behind the Movement

TradingKey
·
Yesterday

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

TradingKey
·
Yesterday

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Yesterday

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

TIPRANKS
·
Oct 07

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

GlobeNewswire
·
Oct 07

Pharma Lobby Sues Trump Administration over Medicare Drug Price Cuts

Reuters
·
Oct 07

Eli Lilly is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 07